Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC. (PubMed, JTO Clin Res Rep) - Oct 21, 2026 - P1 | "Future studies, if pursued, should consider modified dosing strategies, alternative MET and MEK inhibitor combinations, and MET-altered tumors with evidence of MAPK-mediated resistance. NCT05435846."
Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|
|
Collin M Blakely; Edward B Garon; Fei Jiang; Jonathan W Goldman; Jonathan W Riess; Matthew S Lara; Tyiesha Brown
|